The lastest news updates and press releases from Sarborg.
Press Release•12 Mar 2026
Sarborg Curates Rare Disease Signature Database to Expand AI Signature Intelligence Platform
Sarborg Limited (“Sarborg” or the “Company”), today announced the curation of a rare disease signature database containing approximately 1,700 disease signatures, further expanding the datasets available to its proprietary AI Signature Agent platform.
Sarborg Files U.S. Provisional Patent Application for its AI Signature Agent
Sarborg Limited (“Sarborg” or the “Company”), today announced that it has filed a provisional patent application with the United States Patent and Trademark Office (“USPTO”) in relation to its proprietary AI Signature Agent.
Sarborg Expands AI Agentic Signature Platform Beyond Pharmaceuticals into Bacteria and Agrochemicals
The expansion of its proprietary AI Signature Agent platform into additional high-impact sectors, including bacteria and agrochemicals, following the successful deployment of its Pharmaceutical Signature Agent.
Sarborg Develops and Curates “Sarborg 1,600” Gold Standard Disease Signature Database
The curation and development of its proprietary “Sarborg 1,600,” a gold standard database of approximately 1,600 structured disease signatures designed specifically for integration with the Company’s AI Signature Agent.
Sarborg announces the completion of development of its proprietary, AI Signature Agent, initially focused on matching drug and disease signatures within the pharmaceutical sector.
Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and Cybernetics Approach
Conduit Pharmaceuticals partners with SARBORG Limited to leverage artificial intelligence and cybernetics for optimizing key drug development processes, including drug repurposing, discovery, and clinical trial monitoring